연구성과로 돌아가기
2021 연구자 정보 (40 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Seidman, Andrew David (Seidman, AD) |
|
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Shah, Syed Attique (Shah, SA) |
Univ Tartu, Data Syst Grp, Delta Ctr, Inst Comp Sci, Narva Mnt 18-3123, EE-51009 Tartu, Estonia |
ABD-6564-2021 Shah, Syed Attique |
0000-0003-2949-7391 Shah, Syed Attique |
[JCR상위 2.2] Smart traffic control: Identifying driving-violations using fog devices with vehicular cameras in smart cities | SCIE | 2.2 | CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY | mrathore@hbku.edu.qa;paul.editor@gmail.com;smrho@cau.ac.kr;muradkhan23@gmail.com;svimalphd@gmail.com;syed.shah@ut.ee; | ||
|
Shaw Wright, Gail Lynn (Wright, GLS) |
|
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Shparyk, Yaroslav V. (Shparyk, YV) |
|
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Son, Gyung Mo (Son, GM) |
W-2979-2019 Son, Gyung |
|
[JCR상위 2.2] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial. | SCIE | 2.2 | ONCOLOGY | ||||
|
Son, Taeil (Son, T) |
Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Surg, Seoul, South Korea |
|
0000-0002-0327-5224 Son, Taeil |
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | SCIE | 2.2 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Sul, Ji Young (Sul, JY) |
Chungnam Natl Univ Hosp, Dept Surg, Daejeon, South Korea |
|
|
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | SCIE | 2.2 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Tolaney, Sara M. (Tolaney, SM) |
AFZ-2612-2022 Tolaney, S |
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Vatandoust, Sina (Vatandoust, S) |
|
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Vimal, S. (Vimal, S) |
Ramco Inst Technol, Dept CSE, Rajapalayam, Tamil Nadu, India |
E-9551-2016 SHANMUGANATHAN, VIMAL |
0000-0002-1467-1206 shanmuganthan, vimal |
[JCR상위 2.2] Smart traffic control: Identifying driving-violations using fog devices with vehicular cameras in smart cities | SCIE | 2.2 | CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY | mrathore@hbku.edu.qa;paul.editor@gmail.com;smrho@cau.ac.kr;muradkhan23@gmail.com;svimalphd@gmail.com;syed.shah@ut.ee; | ||
|
Wei, Thomas (Wei, T) |
|
|
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. | SCIE | 2.2 | ONCOLOGY | ||||
|
Yook, Jeong Hwan (Yook, JH) |
Univ Ulsan, Asan Med Ctr, Dept Surg, Seoul, South Korea |
|
|
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | SCIE | 2.2 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Ahn, Soyeon (Ahn, S) |
Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Seongnam, South Korea Korea Univ, Coll Med, Seoul, South Korea |
|
|
[JCR상위 2.3] Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort study | SCIE;SSCI | 2.3 | HEALTH CARE SCIENCES & SERVICES;PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | kangsb@snubh.org; | ||
|
An, Sanghyun (An, S) |
Daegu Gyeongbuk Med Innovat Fdn, Lab Anim Ctr, Daegu 41061, South Korea |
|
|
[JCR상위 2.3] Microneedle array with a pH-responsive polymer coating and its application in smart drug delivery for wound healing | SCIE | 2.3 | CHEMISTRY, ANALYTICAL;ELECTROCHEMISTRY;INSTRUMENTS & INSTRUMENTATION | gyuman.kim@knu.ac.kr; | ||
|
Bae, Sang-Geun (Bae, SG) |
|
|
[JCR상위 2.3] Psychological effects of paramedics by experience of managing COVID-19 patients | SCIE | 2.3 | INFECTIOUS DISEASES;MICROBIOLOGY;PHARMACOLOGY & PHARMACY |
페이지 이동: